Viracta Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VIRX research report →
Range $8 – $8
Price Chart
About the company
Viracta Therapeutics, Inc. operates as a precision oncology firm, specializing in the development of therapeutic agents aimed at treating cancers linked to viral infections. The company's leading drug candidate, Nana-val (a combination of nanatinostat and valganciclovir), is currently advancing through multiple clinical trials.
- CEO
- Craig R. Jalbert
- IPO
- 2005
- Employees
- 26
- HQ
- Cardiff-by-the-Sea, CA, US
Get TickerSpark's AI analysis on VIRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $388.70K
- P/E
- -0.01
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.02
- EV/EBITDA
- -0.29
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -128.57%
- ROIC
- -115.54%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-492,000-134.3%
- Op Income
- $-50,693,000
- Net Income
- $-51,058,000-2.6%
- EPS
- $-1.32+0.0%
- OCF Growth
- -12.5%
- FCF Growth
- -12.8%
- 52W High
- $0.19
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- 0.28
- RSI (14)
- 5
- Avg Volume
- 281.45K
No earnings-call transcripts are available for VIRX yet.
- Free Float
- 78.6%
- Shares Outstanding
- 39.74M
- Float Shares
- 31.26M
of shares held by institutions
33 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 273.30K | ▼ 30.68K |
| Hoylecohen, LLC | 14.00K | 0 |
| Planning Capital Management Corp | 7.27K | 0 |
| Rp Management, LLC | 3.70K | 0 |
| Private Ocean, LLC | 3 | ▲ 3 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 25, 24 | ROYSTON IVOR | other | 25,219 |
| Nov 25, 24 | ROYSTON IVOR | other | 25,219 |
| Nov 25, 24 | Pomerantz Roger | other | 9,034 |
| Nov 25, 24 | Pomerantz Roger | other | 9,034 |
| Aug 25, 24 | ROYSTON IVOR | other | 25,219 |
| Aug 25, 24 | ROYSTON IVOR | other | 25,219 |
| Aug 25, 24 | Pomerantz Roger | other | 9,034 |
| Aug 25, 24 | Pomerantz Roger | other | 9,034 |
| Jun 20, 24 | ROYSTON IVOR | other | 50,000 |
| Jun 20, 24 | Borellini Flavia | other | 50,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VIRX coverage
Recent articles, reports, and earnings notes.
No research on VIRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VIRX report →Viracta Therapeutics Announces Wind Down of Operations
globenewswire.com · Feb 5
Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives
globenewswire.com · Dec 26
Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
globenewswire.com · Nov 13
Here's Why Sunesis (VIRX) Is a Great 'Buy the Bottom' Stock Now
zacks.com · Aug 23
Why Is Viracta Therapeutics (VIRX) Stock Up 42% Today?
investorplace.com · Aug 14
Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
globenewswire.com · Aug 14
Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan
globenewswire.com · Aug 14
Viracta Therapeutics Announces New Employment Inducement Grants
globenewswire.com · May 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.